META Pharmaceuticals was invited by AstraZeneca, a biopharmaceutical company, to participate in the event in Hong Kong, alongside the China Medical Innovation Going Overseas Exchange Mission. Guests of the event included the Financial Secretary of the Hong Kong SAR Government, the head of the Hong Kong Office for the Admission of Key Enterprises (OASES), and representatives from the nearly 100 outstanding enterprises.

Speaking at the event, Mr. Paul Chan Mo-po, Financial Secretary of the Hong Kong SAR Government, expressed his expectation that the combination of cutting-edge research by outstanding medical research institutes and experts and scholars in Hong Kong as well as in the Greater Bay Area will bring together more relevant start-ups, injecting new kinetic energy into the region’s pharmaceutical research and development, and creating a more vibrant ecosystem of pharmaceutical innovation.

As a high-growth biopharmaceutical company, META Pharmaceuticals places significant emphasis on various development opportunities and has established subsidiaries in both Hong Kong and China. During the event, the Head of META Pharmaceuticals Affairs introduced the company to the Financial Secretary, Mr. Paul Chan, who warmly welcomed the idea of translating cutting-edge mechanisms from the US into Hong Kong and expressed hope for further communication.

In addition, it received a warm welcome from HKSAR government departments and was invited to the HKSAR government headquarters for a meeting with officials from the Office for the Admission of Key Enterprises in Hong Kong (OASES), the Hong Kong Innovation, Technology, and Industry Bureau (ITIB), the Hong Kong Food and Health Bureau (HKFHB), and other governmental organizations. During these interactions, there were extensive exchanges on topics such as Hong Kong’s policy regarding the introduction of healthcare innovations, the development of innovation and technology, and an overview of the healthcare industry.